MCM
M28 Capital Management Portfolio holdings
AUM
$58.6M
This Quarter Return
-47.15%
1 Year Return
+32.71%
3 Year Return
+247.5%
5 Year Return
–
10 Year Return
–
AUM
$128M
AUM Growth
–
Cap. Flow
+$128M
Cap. Flow
% of AUM
100%
Top 10 Holdings %
Top 10 Hldgs %
97.32%
Holding
12
New
12
Increased
–
Reduced
–
Closed
–
Top Buys
| 1 |
Invivyd
IVVD
|
$41.1M |
| 2 |
Stoke Therapeutics
STOK
|
$12.6M |
| 3 |
Curis
CRIS
|
$12.4M |
| 4 |
Wave Life Sciences
WVE
|
$11.8M |
| 5 |
Rocket Pharmaceuticals
RCKT
|
$10.8M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Invivyd
IVVD
$204M
| $41.1M | 32.12% | +5,665,221 | New | +$41.1M |
|
|
2
Stoke Therapeutics
STOK
$1.08B
| $12.6M | 9.87% | +527,150 | New | +$12.6M |
|
|
3
Curis
CRIS
$20.9M
| $12.4M | 9.7% | +2,608,851 | New | +$12.4M |
|
|
4
Wave Life Sciences
WVE
$1.53B
| $11.8M | 9.23% | +3,765,588 | New | +$11.8M |
|
|
5
Rocket Pharmaceuticals
RCKT
$354M
| $10.8M | 8.44% | +495,280 | New | +$10.8M |
|
6
TG Therapeutics
TGTX
$4.65B
| $10M | 7.82% | +527,000 | New | +$10M |
|
7
BridgeBio Pharma
BBIO
$9.89B
| $7.78M | 6.07% | +466,200 | New | +$7.78M |
|
8
Nektar Therapeutics
NKTR
$568M
| $7.57M | 5.91% | +560,600 | New | +$7.57M |
|
9
Atara Biotherapeutics
ATRA
$84.6M
| $7.2M | 5.62% | +456,865 | New | +$7.2M |
|
10
Leap Therapeutics
LPTX
$12M
| $3.24M | 2.53% | +1,000,000 | New | +$3.24M |
|
|
MRTX
11
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $2.82M | 2.2% | +19,200 | New | +$2.82M |
|
|
NEXI
12
DELISTED
NexImmune, Inc. Common Stock
NEXI
| $615K | 0.48% | +133,442 | New | +$615K |
|